(Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy

BACKGROUND AND PURPOSE: Antagonism of the gastric inhibitory polypeptide (GIP) receptor with daily injection of proline-3 gastric inhibitory polypeptide ((Pro(3))GIP) can reverse or prevent many of the metabolic abnormalities associated with diet-induced obesity-diabetes (diabesity). This study has...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: McClean, P L, Irwin, N, Hunter, K, Gault, V A, Flatt, P R
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2008
Gaiak:
Research Papers
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2584927/
https://ncbi.nlm.nih.gov/pubmed/18695644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjp.2008.317
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak